Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline Research & Development Limited
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A randomised, double-blind, placebo controlled study to investigate the use of mepolizumab (SB240563) in reducing the need for surgery in subjects with severe bilateral nasal polyposis
• To define the effect of mepolizumab in reducing the need for surgery, defined as reduced endoscopic polyp score and symptom score after six months of dosing.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A study of sexual function in sexually active men treated for BPH
To assess the change in sexual function from baseline in sexually active men with at least moderate BPH (international prostate symptom score - IPSS = or > 12) who are treated with DUODART, compared ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A randomised, single blind, placebo-controlled 5-way crossover trial of single doses of intranasal GSK256066 in subjects with seasonal allergic rhinitis (SAR)
To explore the effects of GSK256066 on novel markers of PDE4 inhibition in nasal lavage and scrape samples in mild to moderate allergic rhinitic subjects and determine a dose response relationship
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Study to compare umeclidinium/vilanterol compared with fluticasone propionate/salmeterol in COPD
Primary Objective: Compare the efficacy and safety of UMEC/VI Inhalation Powder (62.5/25mcg oncedaily) with fluticasone propionate/salmeterol (250/50mcg twice-daily) over 12 weeks in subjects wit...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Albiglutide Versus Placebo as Add-on to Intensified Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Mellitus
To evaluate the efficacy of once-weekly albiglutide in providing similar (or better) glycemic control with less hypoglycemia when added to a regimen of intensified basal-bolus insulin therapy compared...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Study to compare umeclidinium/vilanterol compared with fluticasone propionate/salmeterol in COPD
Compare the efficacy and safety of UMEC/VI Inhalation Powder (62.5/25mcg oncedaily) with fluticasone propionate/salmeterol (250/50mcg twice-daily) over 12 weeks in subjects with COPD who have a histor...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A flexible dose study of ezogabine/retigabine immediate release tablets compared to non-active tablets (placebo) as an add-on treatment in adult partial onset seizure patients taking one anti-epilepsy medicine
• To evaluate the efficacy of ezogabine/retigabine IR as an adjunctive treatment for POS in adults with epilepsy who have inadequate control of their seizures with a single AED.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
Not applicable
To evaluate the magnitude of effect (with a level of precision) of inhaled FF 50 mcg versus inhaled placebo OD on growth velocity in prepubertal children over one year of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A multi-centre, randomised, double-blind, placebo-controlled, four-way incomplete block crossover study, to examine efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of single and repeat administration of three inhaled doses (25, 100 and 400 µg once daily) of GW642444
To determine the trough (mean of 23 and 24 hour) FEV1 after 14 day repeat dose inhaled GW642444 (25, 100 and 400 µg) administered once daily in persistent asthmatic subjects.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 5 ans
A study to assess disease pathology and key therapeutic targets in severe asthma
• To evaluate and compare the expression of key severe asthma targets at baseline such as IL-13, IKK2, p38 and CLCA1 in mild to moderate asthmatic vs. severe asthmatic subjects. • To evaluate and com...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
4
5
6
7
8
9
10
Suivant